TQB-2858

N/A

Report date: 2025/05/28 14:38:47

Base Information

Drug NameTQB-2858
Drug Alias NameTQB-2858
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionAnti-Programmed death-ligand 1Anti-TGF-β
TargetsProgrammed death-ligand 1Transforming growth factor beta
Therapy Area/IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsNasopharyngeal Neoplasms +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Active IndicationsN/A
Inactive IndicationsUterine Cervical NeoplasmsEndometrial NeoplasmsNasopharyngeal Neoplasms +[6] 

Other Information

ATC CodeN/A
Related LinksN/A